<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01523496</url>
  </required_header>
  <id_info>
    <org_study_id>09-11-06</org_study_id>
    <nct_id>NCT01523496</nct_id>
  </id_info>
  <brief_title>Vitamin D Supplementation in HIV Youth</brief_title>
  <official_title>Vitamin D Supplementation and HIV-related Complications in Children and Young Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospitals Cleveland Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospitals Cleveland Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the correct dose of Vitamin D to give to prevent
      HIV related complications.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the this study was to compare control dose of vitamin D (low dose of 600 IU/d)
      to supplementation dose (medium dose of 2000 IU/d or higher doses of vitamin D of 4000 IU/d)
      on HIV-related comorbidities including immune activation, inflammation, cardiovascular
      diseases, and metabolic complications in HIV-infected youth.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Serum 25(OH)D3 Levels</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluate the dose-related efficacy of correction of Vitamin D deficiency for 25(OH)D3 levels in a group of HIV-infected children and young adults and a matched healthy control group in a randomized controlled study of different dosing regimens of oral Vitamin D supplementation: control dose (18,000 IU per month) or supplemented dose (medium 60,000IU per month or high dose 120,000IU/month )</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Vitamin D Binding Protein (VDBP)</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluate the dose-related efficacy of vitamin D binding Protein in levels in the blood in a group of HIV-infected children and young adults and a matched healthy control group in a randomized controlled study of different dosing regimens of oral vitamin D supplementation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">190</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>HIV + Young Adults</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All will be HIV+ and receiving randomized dose of vitamin D control dose (low dose) or supplementation dose (vitamin D medium dose or vitamin D high dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV - Controls</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>HIV negative controls will be receiving randomized Vitamin D doses: control vitamin D dose (low dose) or vitamin D supplementation dose (vitamin D medium dose or vitamin D high dose)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D control dose</intervention_name>
    <description>18,000 IU per month</description>
    <arm_group_label>HIV + Young Adults</arm_group_label>
    <arm_group_label>HIV - Controls</arm_group_label>
    <other_name>25(OH)D3 low dose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D supplementation-</intervention_name>
    <description>60,000 IU per month(medium dose) or 120,000 IU/month(high dose)</description>
    <arm_group_label>HIV + Young Adults</arm_group_label>
    <arm_group_label>HIV - Controls</arm_group_label>
    <other_name>25(OH)D3 medium dose or 25(OH)high dose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ages 8-25

          -  Documented HIV-1 infection

          -  On stable antiretroviral therapy for &gt; 3 months

          -  Cumulative antiretroviral therapy of at least 6 months

          -  25(OH)D level &lt; 30 ng/ml at screening

        Exclusion Criteria:

          -  &gt; 400 IU daily regular vitamin D intake

          -  Parathyroid/calcium disorders

          -  Active malignancy

          -  Pregnancy/intent to become pregnant/breastfeeding

          -  Chronic infectious/inflammatory conditions

          -  Creatinine clearance &lt; 50 ml/min

          -  Hemoglobin &lt; 9.0 g/dL

          -  Aspartate aminotransferase and alanine aminotransferase &gt; 2.5 upper limit of normal

          -  Diabetes requiring hypoglycemic agents

          -  Known coronary artery disease

          -  Inability to swallow pills
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Grace McComsey, MD, FIDSA</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals Cleveland Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory Children's Center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Case Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 27, 2012</study_first_submitted>
  <study_first_submitted_qc>January 31, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2012</study_first_posted>
  <results_first_submitted>October 24, 2017</results_first_submitted>
  <results_first_submitted_qc>January 9, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">February 6, 2018</results_first_posted>
  <last_update_submitted>February 5, 2018</last_update_submitted>
  <last_update_submitted_qc>February 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospitals Cleveland Medical Center</investigator_affiliation>
    <investigator_full_name>Grace McComsey</investigator_full_name>
    <investigator_title>Professor of Pediatrics and Medicine, Chief Pediatric Infectious Diseases, Rheumatology and Global Health</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Vitamin D Deficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Calcifediol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>HIV+ With Vit D Supplementation</title>
          <description>HIV-infected adults who were supplemented with vit D ( medium dose: 60,000 IU per month or vitamin D high dose: 120,000 IU/month ) were combined into the supplementation group and compared to the standard control vitamin D dose</description>
        </group>
        <group group_id="P2">
          <title>HIV+ Young Adults With Vitamin D Control Dose</title>
          <description>HIV+ receiving Vitamin D low dose: 18,000 IU per month</description>
        </group>
        <group group_id="P3">
          <title>HIV - With Vitamin D Supplementation</title>
          <description>HIV-uninfected adults who were supplemented with vitamin D: a medium dose of 60,000 IU per month or a higher dose of 120,000 IU/month.</description>
        </group>
        <group group_id="P4">
          <title>HIV - With Vitamin D Control Dose</title>
          <description>HIV uninfected controls receiving Vitamin D low dose: 18,000 IU per month</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="66">The supplementation group includes medium and high dose vitamin D supplementation</participants>
                <participants group_id="P2" count="36"/>
                <participants group_id="P3" count="58">The supplementation group includes medium and high dose vitamin D supplementation</participants>
                <participants group_id="P4" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="46"/>
                <participants group_id="P4" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>A total of 190 subjects were enrolled, including 102 HIV-infected subjects: 66 on vitamin D supplementation dose, 36 on vitamin D control dose and 88 healthy controls: 58 on vitamin D supplementation dose, 30 on vitamin D control dose. By design, groups were well matched for age, sex and race.</population>
      <group_list>
        <group group_id="B1">
          <title>HIV+ With Vit D Supplementation</title>
          <description>HIV-infected adults who were supplemented with vit D ( medium dose: 60,000 IU per month or vitamin D high dose: 120,000 IU/month ) were combined into the supplementation group and compared to the standard control vitamin D dose</description>
        </group>
        <group group_id="B2">
          <title>HIV+ Young Adults With Vitamin D Control Dose</title>
          <description>HIV+ receiving Vitamin D low dose: 18,000 IU per month</description>
        </group>
        <group group_id="B3">
          <title>HIV - With Vitamin D Supplementation</title>
          <description>HIV-uninfected adults who were supplemented with vitamin D: a medium dose of 60,000 IU per month or a higher dose of 120,000 IU/month.</description>
        </group>
        <group group_id="B4">
          <title>HIV - With Vitamin D Control Dose</title>
          <description>HIV uninfected controls receiving Vitamin D low dose: 18,000 IU per month</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="66"/>
            <count group_id="B2" value="36"/>
            <count group_id="B3" value="58"/>
            <count group_id="B4" value="30"/>
            <count group_id="B5" value="190"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.9" lower_limit="17.0" upper_limit="23.6"/>
                    <measurement group_id="B2" value="19.9" lower_limit="15.9" upper_limit="21.6"/>
                    <measurement group_id="B3" value="19.6" lower_limit="14.4" upper_limit="23.2"/>
                    <measurement group_id="B4" value="18.4" lower_limit="14.4" upper_limit="22.2"/>
                    <measurement group_id="B5" value="19.9" lower_limit="15.5" upper_limit="23.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="72"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="29"/>
                    <measurement group_id="B5" value="167"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="58"/>
                    <measurement group_id="B4" value="30"/>
                    <measurement group_id="B5" value="190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Changes in Serum 25(OH)D3 Levels</title>
        <description>Evaluate the dose-related efficacy of correction of Vitamin D deficiency for 25(OH)D3 levels in a group of HIV-infected children and young adults and a matched healthy control group in a randomized controlled study of different dosing regimens of oral Vitamin D supplementation: control dose (18,000 IU per month) or supplemented dose (medium 60,000IU per month or high dose 120,000IU/month )</description>
        <time_frame>6 months</time_frame>
        <population>HIV-infected on vitamin D control or supplementation dose and matched HIV-uninfected group on control or supplementation dose</population>
        <group_list>
          <group group_id="O1">
            <title>HIV Positive on Vit D Control Dose</title>
            <description>HIV+ receiving low vitamin D dose 18,000 IU per month</description>
          </group>
          <group group_id="O2">
            <title>HIV Positive on Vit D Supplementation Dose</title>
            <description>HIV-infected young adults receiving a supplementation dose of vitamin D (either medium dose of 60,000 IU per month or a high dose of 120,000 IU/month)</description>
          </group>
          <group group_id="O3">
            <title>HIV Negative on Vitamin D Control Dose</title>
            <description>HIV negative controls receiving Vitamin D low dose: 18,000 IU per month</description>
          </group>
          <group group_id="O4">
            <title>HIV Negative on Vitamin D Supplementation Dose</title>
            <description>HIV negative controls receiving Vitamin D medium dose: 60,000 IU per month or vitamin D high dose: 120,000 IU/month</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Serum 25(OH)D3 Levels</title>
          <description>Evaluate the dose-related efficacy of correction of Vitamin D deficiency for 25(OH)D3 levels in a group of HIV-infected children and young adults and a matched healthy control group in a randomized controlled study of different dosing regimens of oral Vitamin D supplementation: control dose (18,000 IU per month) or supplemented dose (medium 60,000IU per month or high dose 120,000IU/month )</description>
          <population>HIV-infected on vitamin D control or supplementation dose and matched HIV-uninfected group on control or supplementation dose</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="6" upper_limit="20"/>
                    <measurement group_id="O2" value="22" lower_limit="14" upper_limit="32"/>
                    <measurement group_id="O3" value="7.5" lower_limit="4" upper_limit="13"/>
                    <measurement group_id="O4" value="25" lower_limit="15" upper_limit="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Vitamin D Binding Protein (VDBP)</title>
        <description>Evaluate the dose-related efficacy of vitamin D binding Protein in levels in the blood in a group of HIV-infected children and young adults and a matched healthy control group in a randomized controlled study of different dosing regimens of oral vitamin D supplementation.</description>
        <time_frame>6 months</time_frame>
        <population>HIV-infected children and young adults and matched healthy control group. Results were not analyzed were captured comparing HIV+ young adults on control or supplementation vit D to HIV - controls</population>
        <group_list>
          <group group_id="O1">
            <title>HIV + on Vitamin D Control Dose</title>
            <description>HIV+ receiving vitamin D low dose: 18,000 IU per month</description>
          </group>
          <group group_id="O2">
            <title>HIV + on Vit D Supplementation Dose</title>
            <description>HIV+ receiving Vitamin D supplementation (medium dose: 60,000 IU per month or higher dose: 120,000 IU/month)</description>
          </group>
          <group group_id="O3">
            <title>HIV Negative on Vit D Control Dose</title>
            <description>HIV negative controls on Vitamin D low dose: 18,000 IU per month</description>
          </group>
          <group group_id="O4">
            <title>HIV Negative on Vit D Supplementation Dose</title>
            <description>HIV negative controls on vitamin D supplementation: medium dose of 60,000 IU per month or higher dose of 120,000 IU/month</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Vitamin D Binding Protein (VDBP)</title>
          <description>Evaluate the dose-related efficacy of vitamin D binding Protein in levels in the blood in a group of HIV-infected children and young adults and a matched healthy control group in a randomized controlled study of different dosing regimens of oral vitamin D supplementation.</description>
          <population>HIV-infected children and young adults and matched healthy control group. Results were not analyzed were captured comparing HIV+ young adults on control or supplementation vit D to HIV - controls</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" lower_limit="-17.9" upper_limit="12"/>
                    <measurement group_id="O2" value="-8.9" lower_limit="-41.3" upper_limit="13.3"/>
                    <measurement group_id="O3" value="-11.3" lower_limit="-202" upper_limit="5.4"/>
                    <measurement group_id="O4" value="-11.7" lower_limit="-183.6" upper_limit="-2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected throughout the study duration, at baseline, 6 months, and 12 months.</time_frame>
      <desc>The same definitions are used. Systematic assessments of adverse events were done at each visit date by questionnaires, physical exam and vitamin D levels assessment by the study team. In case of adverse events they were reported to the principal investigator and then assessed in Data Safety and Monitory Board regular meetings.</desc>
      <group_list>
        <group group_id="E1">
          <title>HIV + on Vitamin D Control Dose</title>
          <description>HIV+ receiving vitamin D control dose ( low dose: 18,000 IU per month)</description>
        </group>
        <group group_id="E2">
          <title>HIV+ on Vitamin D Supplementation Dose</title>
          <description>HIV+ receiving vitamin D supplementation doses (medium dose of 60,000 IU per month or higher dose of 120,000 IU/month)</description>
        </group>
        <group group_id="E3">
          <title>HIV - on Vitamin D Control Dose</title>
          <description>HIV negative patients receiving vitamin D control dose (low dose of 18,000 IU per month)</description>
        </group>
        <group group_id="E4">
          <title>HIV- on Vitamin D Supplementation Dose</title>
          <description>HIV negative patients receiving vitamin D supplementation doses (medium dose of 60,000 IU per month or higher dose of 120,000 IU/month)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Limitations to this study include the lack of adherence measures to study drug such as pill counts and the small sample size.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr Grace McComsey</name_or_title>
      <organization>University Hospitals Cleveland Medical Center</organization>
      <phone>216-844-2739</phone>
      <email>Grace.McComsey@UHhospitals.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

